New lung cancer pill targets resistant mutations in early trial
NCT ID NCT06461156
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This Phase 1 study tests a new daily pill called HS-10504 in 230 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR C797S mutation) and has stopped responding to earlier treatments. The main goal is to find the safest dose and check for side effects, while also seeing if the drug can shrink tumors. Participants must have a life expectancy over 12 weeks and be in fairly good health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HS-10504 (a fourth-generation EGFR inhibitor pill taken once daily)
What this could lead to
If it works, this could provide a new treatment option for people with advanced lung cancer that has stopped responding to earlier EGFR-targeted therapies.
What could go wrong
This is an early Phase 1 trial, so the main goals are safety and dosing—not yet proving effectiveness. The drug may not work or could have side effects, and it is only being tested in Chinese patients, so results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University
RECRUITINGGuangzhou, China